News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated
